newsio aggregates and links to original sources. We do not own the original images or content. If you believe content infringes on intellectual property rights, contact us — it will be removed at first notice.

business / news / / Markets Insider

Morgan Stanley maintains a Buy rating on Telix Pharmaceuticals, with a price target of A$24.60.

David Bailey from Morgan Stanley reaffirmed a Buy rating on Telix Pharmaceuticals with a A$24.60 target.

KEY POINTS
COMPANIES
Read the full story on Markets Insider →
Share X LinkedIn

Summarized by Newsio from Markets Insider. How we summarize →